KL
IMUX icon

KCK Ltd’s Immunic IMUX Stock Holding History

KCK Ltd’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6,970
Closed -$242K – 4
2022
Q2 		$242K Hold
6,970
– – 0.34% 3
2022
Q1 		$788K Hold
6,970
– – 0.77% 3
2021
Q4 		$667K Buy
+6,970
New +$628K 0.47% 3

Other funds holding IMUX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
GC
Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

KCK Ltd's IMUX Position: Q3 2022 in Review

KCK Ltd sold out of Immunic (IMUX) in Q3 2022, closing a stake of 6,970 shares — an estimated $242K sold.

KCK Ltd first reported a position in IMUX in Q4 2021 and held it in 3 quarters. The position peaked at $788K in Q1 2022. 65 funds tracked by Wall St. Rank hold IMUX as of Q3 2022.

  • KCK Ltd reported no remaining Immunic position as of Q3 2022 after selling out during the quarter.
  • KCK Ltd sold 6,970 Immunic shares in Q3 2022, an estimated $242K.
  • KCK Ltd first reported a position in Immunic in Q4 2021 and held it in 3 quarters.
  • KCK Ltd's Immunic position peaked at $788K in Q1 2022.
  • 65 funds tracked by Wall St. Rank held Immunic as of Q3 2022.

Based on KCK Ltd's 13F filing for Q3 2022, filed 31 Oct 2022.